VEGFA and diabetes mellitus: Compared to those receiving limited therapy, patients with continuous anti-VEGF treatment group had greater rates of diabetes (p = 0.003), worse baseline vision at the time of RVO diagnosis (p = 0.008), and higher baseline macular thickness at the time of diagnosis (p = 0.04) (Table 1).